11 September 2024
The Russian Ministry of Health has introduced amendments for the second reading of the bill that regulates the biologically active additives (BAA) market. According to these changes, only those BAA’s whose effectiveness has been confirmed by research will be allowed for sale. Expert organizations will evaluate the results of these studies to ensure the supplements’ effects on the body before they are released to the market.
The bill, put forward by the government in May 2023, aims to establish a registry of approved alternative treatments that doctors can suggest to their patients. Manufacturers must demonstrate that BAA’s are crafted with secure and superior raw materials to secure their inclusion in this list.
The explanatory note to the bill emphasizes that this approach is aimed at protecting the health of citizens, since many take BAA’s without supervision, prescribing them to themselves. In early July, the State Duma approved these approaches in the first reading. The Ministry of Health presented its proposals for the second reading, which it sent to Deputy Prime Minister Tatyana Golikova.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
2024 drug approvals: Small companies loom large with several key FDA nods
13 January 2025
Special Regulations for Foreign-Packaged Medicines Extended Until the End of 2025
13 January 2025
Russia Begins Production of Terbium-161 Isotope for Cancer Therapy
10 January 2025
FMBA has begun clinical trials of a vaccine against five serotypes of meningococcus
10 January 2025